Grisnilimab Biosimilar Monoclonal Antibody (CD7) for Research

Cat No.: GMP-Bios-ab-254

Pre-Made Grisnilimab biosimilar, Whole mAb, Anti-CD7 Antibody: Anti-GP40/TP41/Tp40/LEU-9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-254-1mg 1mg 3090

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Grisnilimab biosimilar, Whole mAb, Anti-CD7 Antibody: Anti-GP40/TP41/Tp40/LEU-9 therapeutic antibody
INN Name Grisnilimab
TargetCD7
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2a
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommended2021
CompaniesXenikos
Conditions Approvedna
Conditions ActiveSteroid-refractory acute graft-versus-host disease;Graft-versus-host disease
Conditions Discontinuedna
Development Techna



About target - CD7

1. Protein T-cell antigen CD7

2. Gene CD7

3. Organism Homo sapiens (Human)

Function
Not yet known.